Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Short Interest Rises 71.9%

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 8,346,026 shares, an increase of 71.9% from the September 15th total of 4,853,831 shares. Based on an average trading volume of 2,551,015 shares, the short-interest ratio is presently 3.3 days. Currently, 5.9% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Guggenheim raised their price objective on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Piper Sandler reaffirmed an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Wall Street Zen upgraded Inventiva from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Truist Financial increased their target price on shares of Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Finally, Cantor Fitzgerald began coverage on Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $15.86.

Institutional Investors Weigh In On Inventiva

A number of institutional investors and hedge funds have recently modified their holdings of IVA. Platt Investment Counsel LLC purchased a new position in shares of Inventiva during the 3rd quarter valued at about $45,000. Engineers Gate Manager LP boosted its position in shares of Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after acquiring an additional 43,280 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Inventiva during the 4th quarter valued at about $603,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Inventiva in the first quarter valued at about $1,111,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Trading Up 7.8%

Shares of NASDAQ IVA traded up $0.23 during midday trading on Thursday, reaching $3.10. The company had a trading volume of 1,821,915 shares, compared to its average volume of 932,876. The business’s 50-day simple moving average is $4.11 and its 200 day simple moving average is $4.50. Inventiva has a 1 year low of $2.82 and a 1 year high of $7.98.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The firm had revenue of $0.75 million for the quarter. On average, analysts forecast that Inventiva will post -0.81 earnings per share for the current year.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.